AKT1 and neoplasm: Of the catalytic site inhibitors, AZD5363 has shown activity against GC cell lines in vitro [118, 119], and, as a monotherapy, has mediated partial responses in two patients that harbored tumor mutations in either AKT1 or PI3KCA [120].